-Koen Andries Researcher Activity Profile

Research Author Detailed Information 

Koen Andries Publication Rate By Year

Koen Andries has published 1 paper(s) in 1978, 1 paper(s) in 1980, 1 paper(s) in 2004, 4 paper(s) in 2007, 2 paper(s) in 2008, for a total of 9 research publications in total.

Koen K Andries Author Information

LAST NAME: andries

FIRST NAME: Koen

INITIALS: k

AFFILIATION:

Papers

Koen Andries's Publication Record

1. Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds. Year Published: 2004
Center for Molecular Design (CMD), Janssen Pharmaceutica, Vosselaar, Belgium. plewi@prdbe.jnj.com
2. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Year Published: 2007
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. lenaerts@colostate.edu
3. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Year Published: 2007
Department of Bacteriology, Swedish Institute for Infectious Disease Control, S-171 82 Solna, Sweden. emma.huitric@smi.ki.se
4. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Year Published: 2007
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. lenaerts@colostate.edu
5. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Year Published: 2007
Department of Bacteriology, Swedish Institute for Infectious Disease Control, S-171 82 Solna, Sweden. emma.huitric@smi.ki.se
6. Pathogenicity of hemagglutinating encephalomyelitis (vomiting and wasting disease) virus of pigs, using different routes of inoculation. Year Published: 1978
7. Propagation of hemagglutinating encephalomyelitis virus in porcine cell cultures. Year Published: 1980
8. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). Year Published: 2008
Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research and Development, Campus de Maigremont, BP 615, F-27106 Val de Reuil, France. jbonfant@prdfr.jnj.com
9. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond. Year Published: 2008
Department of Pharmaceutical Biotechnology and Molecular Biology, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium.